Prasugrel STEMI NSTEMI PCI a b s t r a c t Background: Prasugrel, a novel thienopyridine antiplatelet drug significantly reduces rates of stent thrombosis compared to clopidogrel, the current standard therapy, clopidogrel.
Introduction
Acute coronary syndromes (ACS) including unstable angina (UA)/non-ST elevation myocardial infarction (NSTEMI) and
ST-elevation myocardial infarction (STEMI) are a major cause for morbidity and mortality because of cardiovascular disease. 1 Platelet adhesion, activation, and aggregation play a key role in the pathogenesis of atherothrombosis responsible for acute thrombotic events. 2, 3 These factors are especially important in the initiation of the intracoronary thromboses which can result in ACS and the ischemic complications of coronary artery interventions, like recurrent myocardial infarction (MI) and stent thrombosis. 4 Considering the importance of platelets in the pathogenesis of ACS, the role of antiplatelet agents in the management and prevention of the complications after ACS and percutaneous coronary intervention (PCI) cannot be overemphasized. 3 Low-dose aspirin therapy has been the mainstay antiplatelet therapy for many years. It acts by irreversibly acetylating cyclooxygenase 1 (COX-1) enzyme, and thus preventing the conversion of arachidonic acid to thromboxane A2 in the platelets. This results in reduction of overall platelet aggregation at the site of the vascular injury. However, platelet activation can occur by COX-1 independent pathways also like collagen and adenosine diphosphate. 5, 6 This has led to the development of drugs inhibiting these alternate pathways. Antiplatelet drugs belonging to the thienopyridine group which act by inhibiting the ADP-induced platelet aggregation by blocking the P2Y12 receptors are a major advancement in the management of ACS patients undergoing PCI. This group includes 3 drugs: ticlopidine, clopidogrel, and prasugrel. Although ticlopidine was shown to be beneficial, 7, 8 its use is currently limited by the need to take the drug twice daily, poor tolerability, especially gastrointestinal discomfort and serious adverse effects like bone marrow aplasia. 9 A dual antiplatelet therapy of clopidogrel with aspirin is currently the standard of care for this group of patients. 10, 11 Although proven to be beneficial, there have been many reports of recurrent atherothrombotic events while receiving this dual antiplatelet therapy. 12 Additionally, clopidogrel is also associated with three important limitations: a modest antiplatelet effect, substantial interpatient variability and a delayed onset of action. 2 Prasugrel is a novel thienopyridine antiplatelet agent, approved for the treatment of patients with ACS undergoing PCI in 2009. 2 Prasugrel inhibits platelet aggregation more rapidly, more consistently and to a greater extent compared to clopidogrel. 13e16 Several multicentre trials including JUMBO-TIMI 26, 17 PRINCIPLE-TIMI 44, 16 and TRITON-TIMI 38 18 demonstrated that prasugrel shows greater inhibition of platelet aggregation and lower rates of the composite endpoint of death, non-fatal myocardial infarction, and stroke compared with clopidogrel. However, major bleeding was more frequent with prasugrel than with clopidogrel. Considering the availability and increasing usage of prasugrel in India we conducted a study in 82 centers to evaluate efficacy and safety of prasugrel in ACS patients undergoing PCI.
Patients and methods
This was a multicentre, open-labeled, prospective, naturalistic study of the adverse event rate of prasugrel in routine clinical practice, conducted from March 1, 2011 to July 15, 2011. Patients with STEMI or NSTEMI who underwent primary or delayed PCI treated with prasugrel 60 mg loading dose and 10 mg per day maintenance dose were included in the study. The patients were followed up for a period of three months to document adverse events (if any).
In patients >75 years of age, prasugrel was generally not recommended because of the increased risk of fatal and intracranial bleeding and uncertain benefit; however, in highrisk patients (e.g., those with diabetes or prior MI), where its beneficial effects appear to be greater, it was prescribed. Additionally, prasugrel was not advised to patients likely to undergo urgent coronary artery bypass graft surgery (CABG). Patients <60 kg body weight and those on any concomitant medications that increase the risk of bleeding were also excluded from the study.
The outcome measures were stent thrombosis, death and major/minor bleeding over a follow-up period of 3 months. The association of comorbid diabetes and adverse events were specifically studied, considering that diabetes mellitus is a major risk factor for the development of coronary artery disease.
Since prasugrel was used in the setting of normal clinical practice and this was not an experimental study but a naturalistic surveillance, no specific approval was necessary. The trial was performed in accordance with the principles of the Declaration of Helsinki, ethical principles consistent with good clinical practice and following locally applicable regulatory guidelines for post-marketing studies.
Statistical analysis
Descriptive statistical analysis methods have been used. Results on continuous measurements are presented as mean (AE standard deviation) and results on categorical measurements are presented in number (%). The primary outcomes were assessed based on the intention-to-treat (ITT) population, who are defined as patients with at least one dose of study medication and at least one post-baseline assessment for lipid profile. Between groups comparison was assessed by using Chi-square test for parameters on categorical scale. Level of significance was considered as 0.05.
Results

Baseline characteristics
A total of 2592 patients were included in the study from March 1 to April 15, 2011. Of them, 14 were terminated from therapy, and 2578 were followed up for a period of 3 months, that is from June 1 to July 15, 2011, and included in the evaluation. Table 1 shows the baseline parameters of these patients. At baseline, 49.7%, 48.8% and 45.8% of the patients had a history of hypercholesterolemia, hypertension and diabetes mellitus respectively. Additionally, 42.6% had STEMI while 31.6% had UA/NSTEMI. About one-fourth of the patients had a previous history of myocardial infarction. Additionally, vital signs like systolic blood pressure, diastolic blood pressure and pulse rate were within normal limits.
Percutaneous interventional procedures
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Adverse events
There were totally 45 adverse events among 43 patients (1.6%, Table 2 ). The most common events were minor bleeding and chest pain in 9 patients (0.3%) each. This was followed by gastritis (n ¼ 5, 0.2%), weakness (n ¼ 4, 0.2%) and vomiting (n ¼ 3, 0.1%). Most of the events were mild-to-moderate. Additionally, when the association of diabetes mellitus with incidence of adverse events was studied, it was observed that 19 patients each in the diabetes group (n ¼ 1180, 1.6%) and non-diabetes group (n ¼ 1398, 1.4%) had adverse events. The difference was not statistically significant ( p > 0.05). The incidence of adverse events was higher among those aged !75 years (6 out of 48; 12.5%) compared to those <75 years of age (34 out of 2464; 1.4%; p < 0.05).
Discussion
The efficacy of prasugrel as an antiplatelet agent in patients with ACS undergoing PCI has been studied in several trials. Three such trials have led to its approval: JUMBO-TIMI 26, 17 PRINCIPLE-TIMI 44 16 and TRITON-TIMI 38. 18 The key benefits of prasugrel over clopidogrel are that it is more rapid, more consistent and shows greater inhibition of platelet aggregation. 13e16 However, one major concern with the use of prasugrel has been the associated increased risk in bleeding.
In the current study, to document the adverse events rate of prasugrel in clinical practice, it was observed that bleeding and chest pain were the most common adverse events seen in i n d i a n h e a r t j o u r n a l x x x ( 2 0 1 3 ) 1 e5 3   261  262  263  264  265  266  267  268  269  270  271  272  273  274  275  276  277  278  279  280  281  282  283  284  285  286  287  288  289  290  291  292  293  294  295  296  297  298  299  300  301  302  303  304  305  306  307  308  309  310  311  312  313  314  315  316  317  318  319  320  321  322  323  324  325   326  327  328  329  330  331  332  333  334  335  336  337  338  339  340  341  342  343  344  345  346  347  348  349  350  351  352  353  354  355  356  357  358  359  360  361  362  363  364  365  366  367  368  369  370  371  372  373  374  375  376  377  378  379  380  381  382  383  384  385  386  387  388  389  390 IHJ206_proof ■ 29 April 2013 ■ 3/5 9 patients (0.3%) each. In the Joint Utilization of Medications to Block Platelets Optimally (JUMBO-TIMI 26) study, 17 there was no significant difference in non-CABG bleeding between those receiving prasugrel and clopidogrel at 30 days (1.7% vs. 1.2% respectively) or in TIMI major and minor bleeding. However, there were more TIMI minor bleeding events in the prasugrel high-dose regimen group (60 mg loading dose and 15 mg maintenance dose, 3.6%) compared to the intermediate-(60 mg loading dose and 10 mg maintenance dose, 1.5%) or low-dose regimen (45 mg loading dose and 7.5 mg maintenance dose, 2.0%) groups and to the clopidogrel group (300 mg loading dose and 75 mg maintenance dose, 2.4%). However, in The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation (PRINCIPLE-TIMI 44) study 16 in which 201 patients were randomized to receive either prasugrel or clopidogrel, only 2 patients in the prasugrel group had TIMI minor bleeding compared to none in the clopidogrel group. In the TRITON-TIMI 38 study, 18 there was an excess of non-CABG-related major bleeding ( p ¼ 0.03), non-CABG-related TIMI major or minor bleeding ( p ¼ 0.002) and bleeding requiring transfusion ( p < 0.001). Additionally, there was an increase in spontaneous bleeding with prasugrel vs. clopidogrel, but the rates were lower and similar for instrumented bleeding, bleeding related to trauma and intracranial bleeding. By 30 days of treatment, there was no significant difference between the two groups, but after that a significant excess in TIMI major bleeding ( p ¼ 0.34) was observed in the prasugrel group compared to clopidogrel group ( p ¼ 0.03), which was most commonly spontaneous bleeding. However, the recently published results of the TRILOGY-ACS study showed that among patients with UA/NSTEMI, the risks of bleeding was similar between prasugrel and clopidogrel when evaluated longterm, that is up to 30 months. 19 Additionally, this study showed that there was no significant between-group difference in the frequency of other serious adverse events, except for a higher frequency of heart failure in the clopidogrel group. In an Indian study on 220 patients undergoing PCI, there were no major bleeding events with either prasugrel or clopidogrel, but five patients in prasugrel and one patient in clopidogrel group had minor episodes of bleeding. 20 In our study, there was no difference in the incidence of adverse events between patients who had and did not have diabetes mellitus ( p > 0.05). This finding was in line with that of the TRITON-TIMI 38, where there was no excess in TIMI major bleeding in patients with diabetes vs. those who did not. 18 The incidence of adverse events was higher in patients !75 years of age compared to those <75 years (12.5% vs. 1.4%). In the TRITON-TIMI 38, 18 there were higher absolute TIMI major bleeding rates in patients !75 years vs. those who were younger (4.2% versus 3.4%; HR, 1.36; p ¼ 0.24). Additionally, there was a higher rate of spontaneous fatal hemorrhage in the older patients (prasugrel group, 9 vs. clopidogrel group, 0) compared to younger patients (prasugrel group, 5 vs. clopidogrel group, 4).
Number of patients
Number of stents
One more concern with the use of prasugrel has been in patients with a body weight less than 60 kg, in whom the exposure to the active metabolite of prasugrel is increased, which can result in higher risk of bleeding. 18 However, in our study all patients weighed over 60 kg, and this was not a concern.
Based on the findings of the current study, we conclude that prasugrel may be an effective agent in the management of ACS patients undergoing PCI, although it is associated with a minor but definite increase in the risk of bleeding. Additionally, it may be beneficial in patients with diabetes, considering that diabetes is an important risk factor for coronary artery disease and ACS. However, prasugrel has to be cautiously used in patients older than 75 years and weighing <60 kg because of the associated increased bleeding risk.
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